JL I am trying to follow your logic but am having a difficult time to correlate my experience with this sentence of your:
“So as you read this, Amarin is still competing with Generic L because the drug plans are only crediting Vascepa for the MARINE indication..and that will not change until next year.”
So why is it that my pharmacy/insurance company is not substituting generic Lovaza for my Vascepa when I go to fill my script? I think I know the answer and in my opinion that is because Lovaza cannot be a generic substitute for Vascepa as it is not the same API.
JL: what you are proposing makes sense and would be great news if it is the way it will happen...but we were told on this board by several different parties knowledgeable about the workings of pharmacies, health insurance and filling prescriptions that if there is an approved equivalent to branded V that is tier 1 (ie GV), then that is what is filled by the pharmacy on the directive from the health insurers regardless of the health reason why the drug was prescribed. We were told the only possible way around being switched to GV regardless of the indication is if the Doctor prescribes Vascepa and writes DAW on the rx. Otherwise the switch to GV happens. Who is right?
News 
Market Data 
Discover 
